



PB 21 of 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 1) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 20 February 2025

Rebecca Richardson
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1

Schedule 1—Amendments— Additional designated brands effective from 1 August 2025 **2**

<i>National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023</i>	2
--	----------

1 Name

- (1) This instrument is the *National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 1) 2025*.
- (2) This instrument may also be cited as PB 21 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	The day after this instrument is registered.	
3. Schedule 1	1 August 2025.	1 August 2025

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99ADHC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments— Additional designated brands effective from 1 August 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1 Section 5 (after table item dealing with the brand Largactil of the drug Chlorpromazine in the form Tablet containing chlorpromazine hydrochloride 25 mg)

Insert:

Ciloxan	Ciprofloxacin	Ear drops 3 mg (as hydrochloride) per mL, 5 mL	Application to the Ear
---------	---------------	--	------------------------

2 Section 5 (after table item dealing with the brand Depo-Nisolone of the drug Methylprednisolone in the form Injection containing methylprednisolone acetate 40 mg in 1 mL)

Insert:

Metoclopramide HCl Medsurge	Metoclopramide	Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL	Injection
--------------------------------	----------------	--	-----------